Year All20242023202220212020 Date Title Nov 12, 2024 MEI Pharma Reports First Quarter Fiscal Year 2025 Cash Position Sep 19, 2024 MEI Pharma Reports Fiscal Year End 2024 Cash Position Aug 12, 2024 MEI Pharma Engages Oppenheimer & Co. Inc. to Assist in Evaluating Strategic Alternatives Jul 22, 2024 MEI Pharma to Consider Strategic Alternatives May 09, 2024 MEI Pharma Reports Third Quarter Fiscal Year 2024 Results and Operational Highlights Apr 11, 2024 MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344 Apr 11, 2024 MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients Apr 10, 2024 MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum Mar 26, 2024 MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia Feb 13, 2024 MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights Pagination Current page 1 Page 2 Next page › Last page » Displaying 1 - 10 of 11
